Theme: Amalgamation of traditional techniques to advanced studies which redefine BA/BE approach and perception.

BABE 2016

Renowned Speakers

BABE 2016

Conferenceseries LLC invites all the participants across the globe to attend the " 7th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit,” slated on August 29-31, 2016 at Atlanta.

BABE 2016 Conference which is an International Pharma Marketing Industry Conference is a scientific platform to meet fellow key decision makers all-around the Academic Institutions, Healthcare Institutes, Pharmaceutical, Biotech, CROs supply chain, Logistics practitioners making the congress a perfect platform to share experience, foster collaborations through the research talks & presentations to put forward many thought provoking strategies. It's a perfect stage to brainstorm, discover new ideas, search for new skills and a platform to show your capabilities and discoveries to the world. BABE 2016 will be one of the outstanding Bioavailability and Bioequivalence Conferences

Track 1: Clinical Trials

In a clinical trial, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants' behaviour, such as diet. Clinical trials may compare a new medical approach to a standard one that is already available, to a placebo that contains no active ingredients, or to no intervention. Some clinical trials compare interventions that are already available to each other. When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than available alternatives (including no intervention). The investigators try to determine the safety and efficacy of the intervention by measuring certain outcomes in the participants. Preclinical trials are early experiments performed in the lab, prior to being tested in humans. This early research helps to identify potential treatments that are unsafe or ineffective. Clinical trials used in drug development are sometimes described by phase. These phases are defined by the Food and Drug Administration (FDA).

Relevant Conferences:

5th Annual Clinical Trials and Development Asia Congress, Jan 2016, Shanghai,China ; Clinical trails Annual Meeting May 15-18, 2016,Quebec, Canada ; 2nd International Conference on Clinical Trials August 22-24, 2016 Philadelphia ; 6th  Annual Outsourcing in Clinical Trials Europe 2016, May 17-18 2016, Paris, France ; FDA Clinical Trial Requirements Regulations, Compliance and GCP Conference ; 3-4 Sep, 2016, San Diego, CA ; Clinical Trial Supply Europe Conference, Clinical Trial Supply Europe Conference;  7th International Conference and Exhibition on Pharmacovigilance & Clinical Trials September 19-21, 2016 Vienna, Austria. Drug Formulation & Bioavailability Congress, 2nd Drug Discovery & Designing Conference, 7th Pharmacovigilance Conference,  6th Biologics and Biosimilars Conference,  2nd Clinical Trials Conference, World Pharma Congress ; Austrian Pharmaceutical Society; Canadian Society for Pharmaceutical Sciences; Drug Information Association; Georgia Pharmacy Association;

 

Track 2: Pharma Clinical Trials

Clinical trials are used to evaluate potential treatments that have had some effect against disease in the lab, or in animal experiments. The whole point of a clinical trial is to find out if a treatment is effective. The aim of clinical trials is to determine if a treatment works and is safe. By comparing similar groups of people taking different treatments for the same disease it is possible to show whether any benefits are due to the treatment. Effective treatments identified in this way may then become standard practice. Since the research is experimental, those who take part in early studies may not always benefit. Once a new approach has been proven safe and effective in a clinical trial, it may become standard practice. Standard practice is a currently accepted and widely used approach and would require approval by a government body such as the FDA or EMEA.

Relevant Conferences:

Methods in Clinical Cancer Research Workshop, July 23-29, 2016, Vail, Colorado; Workshop on Methods in Clinical Cancer Research (Europe), June 18-24, 2016 , Netherlands; Society for Clinical trails 37th Annual Meeting (2016) May 15-18, 2016,Quebec, Canada ; 2nd International Conference on Clinical Trials August 22-24, 2016 Philadelphia ; 6th  Annual Outsourcing in Clinical Trials Europe 2016, May 17-18 2016, Paris, France ; 5th Annual Clinical Trials and Development Asia Congress, Jan 2016, Shanghai,China ; FDA Clinical Trial Requirements Regulations, Compliance and GCP Conference ; 3-4 Sep, 2016, San Diego, CA ; Clinical Trial Supply Europe Conference, Clinical Trial Supply Europe Conference;  7th International Conference and Exhibition on Pharmacovigilance & Clinical Trials September 19-21, 2016 Vienna, Austria; 3rd Pharmacology Conference, 2nd Biopharmaceutics and Biologic Drugs, (BEBAC)Consultancy Services for Bioequivalence and Bioavailability, Generic Pharmaceutical Association( GPhA )

Track 3: Contract Research Organizations

A contract research organization (CRO) is an organization that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. A CRO may provide such services as biopharmaceutical development, biologic assay development, commercialization, preclinical research, clinical research, clinical trials management, and pharmacovigilance. CROs also support foundations, research institutions, and universities, in addition to governmental organizations. Many CROs specifically provide clinical-study and clinical-trial support for drugs and/or medical devices. CROs that specialize in clinical-trials services can offer their clients the expertise of moving a new drug or device from its conception to FDA/EMA marketing approval, without the drug sponsor having to maintain a staff for these services.

Relevant Conferences:

Outsourcing in Clinical Trials East Coast 2016, May 25-26 2016, King of Prussia, Pennsylvania, USA ; 2nd International Conference on Clinical Trials August 22-24, 2016 Philadelphia ; 6th  Annual Outsourcing in Clinical Trials Europe 2016, May 17-18 2016, Paris, France ; 5th Annual Clinical Trials and Development Asia Congress, Jan 2016, Shanghai,China ; FDA Clinical Trial Requirements Regulations, Compliance and GCP Conference 3-4 Sep, 2016, San Diego, CA ; Clinical Trial Supply Europe Conference;  7th International Conference and Exhibition on Pharmacovigilance & Clinical Trials September 19-21, 2016 Vienna, Austria; European Generic medicines Association, Bioequivalence and Bioavailability forum, Canadian Generic Pharmaceutical Association(CGPA), American Association of Pharmaceutical Scientists (AAPS)

 

Track 4: Challenges in Drug design

Any drug that is taken undergoes a number of chemical reactions in the liver as the body attempts to neutralize foreign substances.  This set of reactions is well characterized, and a great deal of knowledge exists as to how drugs are modified as the body eliminates them.  More importantly, various chemical structures are highly toxic to biological systems, and these are also well characterized.  These constraints must also be taken under consideration as novel drugs are developed. The annual decline in the number of drugs approved for release onto the market in recent years has put pressure on you and your team to refine the drug discovery process and use more effective methods to discover a higher number of successful lead compounds.

Relevant Conferences:

International Conference on Drug Discovery and Designing, Feb 04-05, 2016, Melbourne ; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery  Systems, March 07-09, 2016, Madrid, Spain ; International Conference and Expo on Industrial Pharmacy April 28-29, 2016 Dubai, UAE  ; 7th Annual Global Drug Delivery & Formulation Summit May 23-25, 2016 Dusseldorf, Germany ; 9th World Drug Delivery Summit, June 30-July 02, 2016 New Orleans, Louisiana, USA; International Conference and Expo on Generic Drug Market and Contract Manufacturing, Oct 31- Nov 02, 2016,Valencia, Spain ;5th Medicinal Chemistry & Computer Aided Drug Designing  Conference Dec 1-3, 2016 Chicago, USA National Association of Chain Drug Stores; National Council for Prescription Drug Programs ; National Pharmaceutical Association

Track 5: Challenges in Drug Development

Considerable challenges in drug development, particularly in the face of further organizational changes slated for OGD. A range of legislative and regulatory actions have facilitated consumer access to safe, high-quality generic products, although manufacturing lapses and product quality problems have created critical shortages in important medicines, casting a shadow over the industry's success.

Relevant Conferences:

International Conference on Industrial Pharmacy, Drug Discovery and Development, Jan 28-29, 2016, Dubai ; 7th International Conference on Drug Discovery and Therapy, February 15 - 18, 2016, Dubai, UAE  ; International Conference on Pharmaceutical Drugs and Drug Developments, Mar 30-31, 2016, Istanbul ;  6th Annual Drug Delivery & Formulation Americas Summit April 14-15, 2016 Costa Mesa, CA, US ; 7th Annual Global drug delivery  and formulation summit 23-25 May 2016, Berlin, Germany ; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China ;  International Conference and Expo on Generic Drug Market and Contract Manufacturing, Oct 31- Nov 02, 2016,Valencia, Spain ; 5th International Conference on Medicinal Chemistry & Computer Aided Drug Designing,1-3Dec ,2016,Chicago ; American Association of Pharmaceutical Scientists (AAPS) ; American Association for Clinical Chemistry (AACC); Clinical Trials Information from National Institutes for Health (NIH); National Institute of Standards and Technology (NIST)

 

Track 6: Bioavailability studies

Amount of a substance that becomes available (reaches the target organ or systemic circulation) to an organism's body for bioactivity when introduced through ingestion, inhalation, injection, or skin contact. Rate of bioavailability depends on factors such as the type of the substance and the composition of diet.

Relevant Conferences:

International Conference on Drug Formulation, Bioavailability and Pharmacological Sciences, Jan 25-26, 2016, Istanbul  ; International Conference on Drug Formulation, Bioavailability and Pharmacological Sciences, Jan 25-26, 2016, Istanbul ; 5th Drug Formulation & Bioavailability, January 25 - 27, 2016, Boston, Massachusetts, USA; International Conference on Clinical Pharmacology and Drug Design, May 12-13, 2016, Amsterdam; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China ; 3rd International Conference on Health Informatics and Technology June 27-29,2016, New Orleans, USA ; 2nd International Conference and Expo on Drug Discovery & Designing October 24-26, 2016 Istanbul ; 5th European Food Safetyand Standards Conference, Oct 24-26, 2016,Valencia, Spain; Bioequivalence and Bioavailability forum; FDA Office of Surveillance and Epidemiology; Drug Watch; ORPHANET Parenteral Drug Association; Pharm GKB; US Food and Drug Administration (FDA)

 

Track 7: Bioequivalence studies

If two medicines are bioequivalent there is no clinically significant difference in their bioavailability. Although bioequivalence is most commonly discussed in relation to generic medicines, it is important to note that bioequivalence studies are also performed for innovator medicines in some situations such as: between early and late clinical trial formulations or between the formulations used in clinical trials and the product to be marketed for new medicines when changes in formulation have occurred after an innovator product has been approved, for example a change in one or more excipients (inactive ingredients)

Relevant Conferences:

International Conference on Pharmacy and Pharmacokinetics, Jan 26-27, 2016, Jeddah ; 2nd International Conference and Exhibition on Pharmacology and Ethnopharmacology, May 02-04, 2016, Chicago, USA ; 7th annual global drug delivery and formulation summit 23-25th May2016,Berlin Germany ;  International Conference on Clinical Pharmacology and Drug Design, May 12-13, 2016, Amsterdam ; 7th International Conference and Exhibition on Pharmacovigilance & Clinical Trials, September 19-21, 2016 ,Vienna, Austria ; International Conference on Advanced Pharmaceutical Engineering and Pharmacokinetics, Dec 01-02, 2016, Lagos 8th Global Pharmacovigilance Summit March 6-8, 2017 Brisbane, Australia; American Thyroid AssociationGeneric Pharmaceutical Association ( GPhA);  European Generic medicines Association; Therapeutics Goods Administration (TGA), France Generic Medicines AssociationAssociation of Innovative Pharmaceutical ManufacturersPortuguese Generic Medicines AssociationAssociation of the Dutch Generic Medicines IndustryThe British Generic Manufacturers Association

 

Track 8: Why BA/BE studies

This section provides recommendations to the applicants, who undertake bioequivalence studies and/or who wish to request a waiver of in vivo bioequivalence studies for immediate release solid oral dosage forms.  Guidance herein explains how the bioequivalence studies should be performed, and when biowaivers can be requested in the context of the WHO Prequalification of Medicines Programme. Data on bioequivalence provide a bridge between two or more pharmaceutical equivalents when safety and efficacy data are available for one of the products, but not for the other. For multisource products bioequivalence studies/bioequivalence assessment conferences are necessary to ensure therapeutic equivalence and interchange ability of the products. Bioequivalence can also be demonstrated by comparative clinical studies, pharmacokinetic studies or appropriate in vitro studies. Relevant Conferences:

International Conference on Drug Formulation, Bioavailability and Pharmacological Sciences, Jan 25-26, 2016, Istanbul  ; 5th Drug Formulation & Bioavailability ,January 25 - 27, 2016, Boston, Massachusetts, USA ; 2nd International Conference and Exhibition on Pharmacology and Ethnopharmacology , May 02-04, 2016, Chicago, USA ; 3rd International Conference on Health Informatics and Technology June 27-29,2016, New Orleans, USA ; 7th International Conference and Exhibition on Pharmacovigilance & Clinical Trials, September 19-21, 2016, Vienna, Austria ; 5th European Food Safety and Standards Conference, Oct 24-26, 2016,Valencia, Spain. 8th Global Pharmacovigilance Summit March 6-8, 2017 Brisbane, Australia. BEBAC Consultancy Services for Bioequivalence and BioavailabilityBioequivalence and Bioavailability forum; American Association for Clinical Chemistry (AACC);  American Association of Pharmaceutical Scientists (AAPS)

Track 9: Factors Affecting Bioavailability

In pharmacology, bioavailability is a subcategory of absorption and is the fraction of an administered dose of unchanged drug that reaches the systemic circulation, one of the principal pharmacokinetic properties of drugs.  There are many recent advances and factors affecting Bioavailability. It includes Absorption, metabolism and Food effect of Drugs. Physico-chemical factors, first pass metabolism and Energy dependent efflux transporters are also discussed in BA/BE World Congress.

Relevant Conferences:

International Conference on Drug Formulation, Bioavailability and Pharmacy, Jan 18-19, 2016, London ; International Conference and Expo on Industrial Pharmacy April 28-29, 2016 Dubai ; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 4th Annual Conferences on European Pharma Congress June 13-15, 2016 Berlin ; 9th World Drug Delivery Summit June 30-July 02, 2016 New Orleans, USA ; International Conference and Expo on Generic Drug Market and Contract Manufacturing, Oct 31- Nov 02, 2016,Valencia, Spain ; International Conference on Chemical and Food Engineering ,Oct 29-30, 2015,  Paris ; Generic Pharmaceutical Association ( GPhA ), European Generic medicines Association, Bioequivalence and Bioavailability forum, Canadian Generic Pharmaceutical Association (CGPA)

 

Track 10: Assessment of Bioequivalence

Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed.

Relevant Conferences:

International Conference on Drug Formulation, Bioavailability and Pharmacy, January 18-19, 2016,London ; International Conference on Pharmacology and Pharmaceutical Medicine, Jan 18-19, 2016, San Diego ; Respiratory Drug Delivery, April 17-21, 2016 Phoenix, Arizona; 2nd International Conference on Respiratory and Pulmonary Medicine, May 09-10, 2016, International Conference on Environmental Toxicology and Ecological Risk Assessment, August 25-26, 2016,Sao Paulo, Brazil; FIP World Congress of Pharmacy and Pharmaceutical Sciences 2016, 28 August - 1 September 2016, Buenos Aires, Argentina; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR ,September 12-14, 2016,San Antonio, USA ;Asia Pacific Mass Spectrometry Congress October 13-15, 2016 Kuala Lumpur, Malaysia ; Chicago, USA ; International Conference on Pharmacology and Pharmaceutical Medicine, Dec 23-24, 2015, Dubai;  Generic Pharmaceutical Association (GPhA); Canadian Generic Pharmaceutical Association(CGPA); Southern African Generic Medicines AssociationThe Danish Generic Medicines Industry Association

                                                                  

Track 11: Study design

It includes randomized, two-period, two-sequence, single dose cross-over design, parallel design and replicate designs. Absolute and Relative bioavailability are discussed. Pharmacokinetics and Pharmacodynamics of the study designs make an important role.

Relevant Conferences:

International Conference on Pharmacy and Pharmacokinetics, January 26-27, 2016 Jeddah ; 29th Annual Pharmacokinetics for Pharmaceutical Scientist, 29 Feb – 4 March 2016, San Francisco, CA ; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; International Conference on Advanced Pharmaceutical Engineering and Pharmacokinetics, Aug 08-09, 2016, Seattle ;7th International conference and exhibition on Pharmacovigilance & Clinical Trials, September 19-21, 2016 Vienna, Austria ; ; International Conference and Expo on Generic Drug Market and Contract Manufacturing, Oct 31- Nov 02, 2016,Valencia, Spain ; International Conference on Molecular Modeling and Drug Design, Nov 12-13, 2017, Kyoto ; International Conference on Advanced Pharmaceutical Engineering and Pharmacokinetics, Dec 01-02, 2016, Lagos; 8th Global Pharmacovigilance Summit March 6-8, 2017 Brisbane, Australia. Canadian Society for Pharmaceutical Sciences; Drug Information Association; Georgia Pharmacy Association; Illinois Pharmacists Association

Track 12: Bioequivalence Protocols

Both bioavailability and bioequivalence focus on the release of a drug substance from its dosage form and subsequent absorption into the systemic circulation. Bioavailability and Bioequivalence studies are required by regulations to ensure therapeutic equivalence between a pharmaceutically equivalent test product and a reference product. Several in vivo and in vitro methods are used to measure product quality.

Relevant Conferences:

International Conference on Pharmacology and Pharmaceutical Medicine, January 18-19, 2016, San Diego .International Conference on Drug Formulation, Bioavailability and Pharmacological Sciences, Jan 25-26, 2016, Istanbul ; International Conference on Drug Formulation, Bioavailability and Pharmacy, Jan 18-19, 2016, London;  Ethnopharmacology 2016 May 2-4, 2016 Chicago, USA; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; Pharma Europe 2016 July 18-20, 2016 Berlin, Germany ; 7th International conference and exhibition on Pharmacovigilance & Clinical Trials September 19-21, 2016 Vienna, Austria ; 5th International Conference and Exhibition on Pharmaceutical Regulatory Affairs August 03-05, 2015 Florida, USA; Annual Oral Drug Formulation Innovations Summit, September 29th- 30th, 2015, Philidelphia ; International Conference on Pharmacology and Pharmaceutical Medicine, Dec 23-24, 2015, Dubai; American Association of Pharmaceutical Scientists (AAPS); Clinical Trials Information from National Institutes for Health (NIH); National Institute of Standards and Technology (NIST); Austrian Pharmaceutical Society;

 

Track 13: Managing BA/BE Studies

BA/BE studies are needed by regulations to guarantee remedial proportionality between a pharmaceutically comparable test item and a reference item. BA/BE studies are finished Early and late clinical trial definitions, Formulations utilized as a part of clinical trial and steadiness studies. Everybody has more heaped on their plate than any time in recent remembrance, and numerous consultant discover themselves always re-organizing their work exercises.

BA/BE studies and conferences are required by regulations to ensure therapeutic equivalence between a pharmaceutically equivalent test product and a reference product. BE studies are done for Early and late clinical trial formulations, Formulations used in clinical trial and stability studies,  if different Clinical trial formulations and to-be-marketed drug product When it comes to  cost and productivitymetrics, it’s often said that what gets measured gets done. Part of this is human nature. Everyone has more piled on their plate than ever, and many workers find themselves constantly re-prioritizing their work activities

Relevant Conferences:

18th International Conference on Pharmaceutical Sciences and Pharmacology Jan 21-22, 2016 Paris, France; American Society for Clinical Pharmacology and Therapeutics , March 9-12, 2016, California, United States; International Conference on Pharmacology, Toxicology and Pharmaceutics, May 23-24, 2016 London ; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Food Safety and Regulatory Measures, June 06-08, 2016, London, UK ; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Antonio, USA ; International Conference and Expo on Generic Drug Market and Contract Manufacturing, Oct 31- Nov 02, 2016,Valencia, Spain ; International Conference on Pharmacology and Molecular Genetics, Dec 01-02, 2016, Lagos; ORPHANET Parenteral Drug AssociationPharm GKBUS Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC);

Track 14: Global  BA/BE Studies

Bioavailability is a pharmacokinetic term that describes the rate and extent to which the active drug ingredient is absorbed from a drug product and becomes available at the site of drug action. The bioavailability of a drugsubstance formulated into a pharmaceutical product is fundamental to the goals of dosage form design and essential for the clinical efficacy of the medication. Bioavailability determination are performed by drug manufacturers to ensure that a given drug product will get the therapeutic agent to its site of action in an adequate concentration. Bioavailability is of clinical and regulatory interest. Genetic makeup of a patient importantly influence inherent pharmacokinetic, ultimately giving rise to inter patient variation in drug absorption, distribution, biotransformation, and elimination.

Relevant Conferences:

2nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey ; 6th Pharmacovigilance Congress , September 28-30, 2016 , Toronto, Canada; 2nd International Conference on Clinical Trials, August 22-24, 2016 ,  Philadelphia, USA; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd Drug Discovery & Designing Conference , November 08-09, 2016 Istanbul, Turkey; International Conference on Protein Engineering October 26-28, 2015 Chicago, USA;  Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 12th Biotechnology Congress November 14-15, 2016 San Francisco, USA ; 2nd International Conference and Expo on Parenterals & Injectables ; December 05-07, 2016 Dallas, TX, USA; Therapeutics Goods Administration (TGA);  Canadian Generic Pharmaceutical Association (CGPA); Bioequivalence and Bioavailability forum; Drug Watch; BEBAC Consultancy Services for Bioequivalence and Bioavailability

 

Track 15: Nutrient Bioavailability

Nutrient Bioavailability refers to the proportion of a nutrient that is absorbed from the diet and used for normal body functions. It includes enhancers of nutrient bioavailability, factors playing a critical role in absorption of nutraceuticals and herbal products. The role of BPDM nutrient bioavailability is discussed under this track.

Relevant Conferences:

International Conference on Pharmaceutical Drug Design, Development and Technology,08-09 May, 2016, Dubai ; International Conference on Drug Design, Development and Clinical Pharmacy, May 08-09, 2016, Dubai ; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics, June 09-10, 2016,Dallas, USA ; 6th International Conference and Exhibition on Analytical & Bioanalytical Techniques  September 1-3, 2015 Valencia, Spain ; International Conference and Expo on Generic Drug Market and Contract Manufacturing,Oct 31- Nov 02, 2016,Valencia, Spain; International Conference On Food And Environmental Sciences Dec 2016, Atlanta, USA; BEBAC Consultancy Services for Bioequivalence and BioavailabilityAmerican Thyroid AssociationGeneric Pharmaceutical Association ( GPhA);  European Generic medicines Association

Track 16: Advances in Bioavailability

In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

Relevant Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques March 17-18, 2016 London, UK;  International Conference on Pharmaceutical Drugs and Drug Developments, Mar 30-31, 2016, Istanbul ; 2nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey ;  6th Pharmacovigilance Congress , September 28-30, 2016 , Toronto, Canada;  2nd International Conference on Clinical Trials, August 22-24, 2016 ,  Philadelphia, USA;  International Conference on Clinical Pharmacology and Computer Aided Drug Development, Apr 08-09, 2016, Dubai ; International Conference on Pharmaceutical Regulatory Affairs, April 29-31,Doha ; 2nd International Conference on Food Safety and Regulatory Measures, June 06-08, 2016,London, UK ; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics, June 09-10, 2016,Dallas, USA ; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Antonio, USA; Bioanalytical Focus Group and Ligand Binding AssayAmerican Association of Pharmaceutical Scientists (AAPS);  Royal Netherlands Chemical SocietyThe European Bioanalysis Forum

 

Track 17: Biosimilars

A biosimilar is a biologic therapeutic item which is duplicate of a unique item that is produced by an alternate organization. Biosimilars are authoritatively sanction forms of unique "discoverer" items, and can be produced when the first item's patent terminates. Reference to the pioneer item is a fundamental part of the approbation.

Relevant Conferences:

Summit on Biosimilars, 27-28 Jan 2016, Washington, USA; Biosimilar Drug Development World Europe, 10-11 Feb 2016 Barcelona, Spain ; Biosimilars & Biobetters Congress, 18-19 April 2016, London, UK ; Respiratory Drug Delivery , April 17 – 21 , 2016, Phoenix,USA; American Society for Pharmacology and Experimental Therapeutics, April 2 - 6, 2016, San Diego, California, USA ; World Biosimilar Congress , 24-25 May 2016 , San Diego, USA ; 2nd International Conference on Current Trends in Mass Spectrometry May 09-11, 2016 Chicago, USA  World Congress and Expo on Medical Devices, September 21-22, 2015 Florida, USA ; 6th International Conference and Exhibition on Biologics and Biosimilars ,September 15-17, 2016 San Antonio, USA ; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; Generic Pharmaceutical Manufacturers AssociationInternational Generic Pharmaceutical AllianceEuropean Association of generic drugsCanadian Association of generic drugs; Japan Association of generic drugs

Track 18: Clinical Pharmacology and Therapeutics

Clinical pharmacology is the science of drug use in humans. Clinicians of all specialties pre-scribe drugs on a daily basis, and this is both one of the most useful but also one of the most dangerous activities of our professional lives. This track includes recent developments on behavioural pharmacology, Clinical toxicology, Clinical and experimental pharmacology, Clinical drug developments & therapeutics and also recent developments on posology. Pharmacogenetics is the study of inherited genetic differences in drug metabolic pathways which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects which will be discussed under this track.

Relevant Conferences:

International Conference on Pharmaceutical Sciences and Pharmacology, Jan 21-22, 2016, Paris; International Conference on Pharmacology, Medicinal and Pharmaceutical Sciences, Feb 25-26, 2016, London ; International Conference on Pharmacological Sciences, Feb 25-26, 2016,Dubai ; International Conference on Pharmacology and Biochemistry, Feb 11-12, 2016, Kuala Lumpur; International Conference on Medicinal Chemistry and Molecular Pharmacology, Mar 01-02, 2016, Miami; 2nd International Conference and Exhibition on Pharmacology and Ethnopharmacology, May 02-04, 2016,Chicago, USA ; 3rd World Congress on Pharmacology ,August 08-10, 2016,Birmingham, UK ; 4th Global Experts Meeting on Neuropharmacology, September 15-17, 2016,San Antonio, USA ; 5th Global Summit on Toxicology & Applied Pharmacology, September 19-21, 2016,Las Vegas, USA ; 6th Euro-Global Summit on Toxicology & Applied Pharmacology ,October 27-29, 2016,Rome, Italy; American Society for Clinical Pharmacology and Therapeutics ; California Pharmacists Association ; International Pharmaceutical Federation (FIP)

 

 

 

 

Conferenceseries LLC invites all the participants across the globe to attend the 7th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit August 29-31, 2016, at Atlanta, USA which includes prompt keynote presentations, Oral talks, Poster presentations, Workshops and Exhibitions.

BABE 2016 Conference which is an International Pharma Marketing Industry Conference is a scientific platform to meet fellow key decision makers all-around the Academic Institutions, Healthcare Institutes, Pharmaceutical, Biotech, CROs supply chain, Logistics practitioners making the congress a perfect platform to share experience, foster collaborations through the research talks & presentations to put forward many thought provoking strategies. It's a perfect stage to brainstorm, discover new ideas, search for new skills and a platform to show your capabilities and discoveries to the world. BABE  2016 will be one of the outstanding Bioavailability and Bioequivalence Conferences.The Bioavailability Bioequivalence Research Center and BA/BE global conferences aims to become a regional center of excellence for assuring the safety and efficacy of generic pharmaceutical products for human use. It plays a key role in the drug development period for both new drug products and their generic equivalents. These studies are also important in the post approval period in the presence of certain manufacturing changes. Information in the overall set of data that ensure the availability of safe and effective medicines to patients and practitioners can be discussed in bioavailability meeting.

Why to attend???

With all the scientific people over the world focused on learning about Pharmaceutical Current and Novel trends and advanced strategies in Pharma Marketing Industry.This is a best globalised opportunity to reach the largest assemblage of participants from the Pharma community. We anticipate participants, renowned speakers and eminent delegates across the globe attending the conference to share their valuable presentation and galvanize the scientific community. BABE 2016 is a 3-day event offering the Exhibition at venue to showcase the new and emerging technologies and Conduct presentations, distribute information, meet with potential scientists, make a splash with new drug developments, and receive fame and recognition. Our services have always met with great achievement in Business Conferencing. World-renowned speakers, the most recent and advanced techniques, developments, and the newest updates are the prominent features of the conference.

Target Audience:

  • CRO
  • Professors, Associate Professors, Asst Professors
  • PhD Scholars
  • Graduates and Post Graduates
  • Directors, CEO’s of Organizations
  • Association, Association presidents and professionals
  • Noble laureates in Health Care and Medicine
  • Bio instruments Professionals
  • Research Institutes and members
  • Supply Chain companies
  • Manufacturing Companies

 

Summary:

BABE 2016 welcomes attendees, presenters, and exhibitors from all over the world to Atlanta, USA. We are delighted to invite you all to attend and register for the “7th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit” (BABE 2016) which is going to be held during August 29-31, 2016 at Atlanta. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the BABE 2016, where you will be sure to have a meaningful experience with scholars from around the world. All members of the BABE 2016 organizing committee look forward to meeting you in Atlanta, USA.

For more details please visit- http://bioavailability-bioequivalence.pharmaceuticalconferences.com/

Scope and Importance  :

‘Bioavailability and Bioequivalence’ is an international forum to present and discuss current perspectives in drug research. Bioequivalence Conference provides the scope for opportunities to learn progressed by international scientists and academicians. The Bioavailability Bioequivalence Research Center and BA/BE global conferences aims to become a regional center of excellence for assuring the safety and efficacy of generic pharmaceutical products for human use. It plays a key role in the drug development period for both new drug products and their generic equivalents. These studies are also important in the post approval period in the presence of certain manufacturing changes. Information in the overall set of data that ensure the availability of safe and effective medicines to patients and practitioners can be discussed in bioavailability meeting. 

The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

  • An overview of the global market for generic  drug including coverage of therapeutic
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.The North American market is estimated to reach nearly $73 billion in 2011 and is expected to increase at a 7.9% compound annual growth rate to reach nearly $107 billion in 2016.
  • The United States is currently spending almost $250 billion a year for prescription drugs. If drugs were sold in a competitive market, without government-imposed patent monopolies, this might achieve savings up to $200 billion a year.

 

Fig 1

 

Major Associations :

  • Bioanalytical Focus Group and Ligand Binding Assay
  • American Association of Pharmaceutical Scientists (AAPS)
  • Royal Netherlands Chemical Society
  • The European Bioanalysis Forum
  • BEBAC Consultancy Services for Bioequivalence and Bioavailability
  • American Thyroid Association
  • Generic Pharmaceutical Association
  • FDA
  • European Generic medicines Association.
  • Therapeutics Goods Administration (TGA)
  • European Economic Area
  • Canadian Generic Pharmaceutical Association (CGPA)
  • Bioequivalence and Bioavailability forum
  • FDA Office of Surveillance and Epidemiology
  • Drug Watch
  • ORPHANET Parenteral Drug Association
  • PharmGKB
  • US Food and Drug Administration (FDA)
  • American Association for Clinical Chemistry (AACC)
  • American Association of Pharmaceutical Scientists (AAPS)
  • Clinical Trials Information from National Institutes for Health (NIH)
  • National Institute of Standards and Technology (NIST)

 

BABE-2015

We would like to thank all of our wonderful speakers, conference attendees, students, associations and guests for making BABE-2015 a wonderful event!

OMICS International hosted BABE-2015 which was scheduled during August 17-19, 2015 at Chicago, USA with the theme “Advance Approaches in Discussion of Current Issues & Future Possibilities in Bioavailability and Bioequivalence Studies”. The conference had several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from various leaders from the fields  of Bioavailability and Bioequivalence Research Centres, Professors, Companies, Researchers, students and Research Professionals, who made this event a Grand Success.

Various sessions were carried out with multiple presentations from speakers all around the world. Major Sessions to be discussed were:

  • Emerging Bioavailability and Bioequivalence Studies
  • Bioanalytival Methodology
  • Contempory challenges of drugdesign ,discovery and development
  • Regulatory policies procedures prerequisites for clinical research
  • Managing BA/BE studies
  • Relevance of Genetics to BA/BE in Drug Development
  • Bioavailability, Bioequivalence and Drug Product Selection
  • Advances in Assessment of Bioequivalence
  • Need for conducting  BA/BE studies
  • Metabolic Pathways and Changes in Nutrient Bioavailability
  • Clinical Pharmacology and Therapeutics
  • Study Designs
  • Factors Affecting Bioavailability

The conference was initiated with a series of lectures delivered by both Honorable Guestsand members of the Keynote forum. The list includes:

  • Paramjeet Kaur, U.S. Food and Drug Administration, USA
  • Jim Jingjun Huang, Ascendia Pharmaceuticals, USA
  • Keith Gallicano, Novum Pharmaceutical Research Services, USA

Series of workshops includes expert presentation by Paramjeet Kaur, U.S. Food and Drug Administration, USA, on “Biowaiver approaches for generic drug products in the US: case studies”, Jim Jingjun Huang, Ascendia Pharmaceuticals, USA on “Rational design of amorphous solid dispersion for solubility and bioavailability enhancement”, Keith Gallicano, Novum Pharmaceutical Research Services, USA on “Bioequivalence of topical corticosteroids: Design and data analysis challenges with the vasoconstrictor assay”

 

OMICS International offers its heartfelt appreciation to the Organizing Committee Members, namely Sinerik Ayrapetyan, Mirko Diksic, Wolfgang Sadee, Mirko Diksic who supported us throughout the event. Also, it would be incomplete without thanking all our expert presenters from all around the world which includes various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums.

With the grand success of BABE-2015, OMICS International is proud to announce the “7th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit " to be held during August 29-31, 2016 at Atlanta, USA.

For More details visit: http://bioavailability-bioequivalence.pharmaceuticalconferences.com/

 

Past Reports  Gallery  

BABE-2014

OMICS International 5th World Congress on Bioavailabity and Bioequivalence: Pharmaceutical R&D Summit at DoubleTree by Hilton Baltimore, USA during Sep 29 - Oct 01, 2014 was organized with a focus on Critical Review on Recent Developments in Bioavailability and Bioequivalence Studies was a great success where eminent keynote speakers from various reputed institutions made their resplendent presence and addressed the gathering. BABE-2014 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of Pharmaceutics and Clinical research. BABE-2014 Organizing Committee would like to thank the Moderator of the conference, Songon An, University of Maryland, Baltimore County, USA who contributed a lot for the smooth functioning of this event.

OMICS International would like to convey a warm gratitude to all the Honorable guests of BABE-2014:     

Michael Retsky, Harvard School of Public Health, USA
Luigi Silvestro, 3S-Pharmacological Consultation & Research GmbH, Germany
Jim Jingjun Huang, Ascendia Pharmaceuticals, USA

The highlights of the conference were its educative and effectual keynote lectures by:

Michael Retsky, Harvard School of Health, USA
Georg F. Weber, University of Cincinnati Academic Health Center, USA
Jim Jingjun Huang, Ascendia Pharmaceuticals, USA
P Venkataraman , SRM Medical College, India

OMICS International, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance in the field of Bioavailability and Bioequivalence Studies and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours. We would like to thank the Poster Competition Judge Dr. Yahdiana Harahap, University of Indonesia, Indonesia for her valuable time.

Best Poster Winner:

Syed N Alvi, King Faisal Specialist Hospital & Research Centre, Saudi Arabia.

OMICS International also took the privilege of felicitating BABE-2014 Organizing Committee,Editorial Board Members of Journal of Bioequivalence & Bioavailability  |  Journal of Bioanalysis & Biomedicine  and  Pharmaceutica Analytica Acta, Keynote Speakers, Chair and Co-Chairs and Moderator whose support made conference a great success. Our special gratitude to our Silver Sponsor Lambda Therapeutic Research Ltd., India and our Media partners Absave, Bio save, China Exhibition, Current Partnering, Pharma Asia and pharmaphorum.

With the enormous feedback from the participants and supporters of  BABE-2014, OMICS Group Conferences is glad to announce its 6th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit (BABE-2015) from Aug 17-19, 2015 at Chicago, USA


Past Reports  Gallery  

BABE-2013

4th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit, hosted by the OMICS Group was successfully held during May 20-22, 2013 in Beijing, China. Outstanding response and active participation was received from the Researchers, Leaders from Pharmaceutical R&D sectors, Government Organizations, and Principal Investigators. Editorial Board Members of OMICS Group helped in making this meeting a huge success. 

Keynote Speakers:

  • Michael Retsky, Harvard School of Public Health, USA
  • Yibin Feng, The University of Hong Kong, China
  • Shein-Chung Chow, Duke University School of Medicine, USA
  • Sinerik Ayrapetyan, UNESCO, Armenia

A series of invited lectures by Honorable guests and members of the Keynote forum marked the commencement of the event. Keynote session was very prolific to the scientific community and they lifted up solutions and illustrated a way on the theme Advanced Discussions of the Current Issues & Analyzing the Novel Approaches of Bioavailability & Bioequivalence"

Scientific sessions established active contribution from researchers and principal investigators, and the Poster presentations were phenomenally excellent with the enthusiastic students and fellow researchers. It established a new prospect and hopes on ongoing projects in Bioavailability and Bioequivalence and paved a new path to Pharmaceutical R&D.

OMICS Group felicitated all the Organizing Committee Members and Editorial Board Members who enthusiastically participated in the conference and made this meeting a huge success.

OMICS Group on behalf of OCMs and EBMs congratulates all the Best Poster Awardees for their outstanding contribution in the field of Pharmaceutics and simultaneously encourages all the participants who tried to put their efforts in poster presentations and wish them success for their future research.

Best Poster Awardees:

  • Ning Wang, The University of Hong Kong, China
  • Liberato Brum Junior, Prati-donaduzzi Pharmaceutical Industry Co., Ltd., Brazil
  • Syed Naseeruddin Alvi, King Faisal Specialist Hospital and Research Centre, Saudi Arabia
  • Shanmugam, JSS College of Pharmacy, India
  • L. Priyanka Dwarampudi, JSS College of Pharmacy, India

BABE-2013 Organizing Committee Members hearts fully thank all the supporters and media partners in promotion of the conference.

With the huge optimistic response from scientific fraternity, industries, renowned personalities and Editorial Board Members of OMICS Group across the world, we would like to proudly announce

“5th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit” during Sep 29 - Oct 01, 2014 in Baltimore, USA

 

We wish to pioneer a way to another outstanding event in USA.


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date August 29-31, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Media Partners

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
babe@conferenceseries.net
Sponsors / Exhibiting / Advertising.
babe@conferenceseries.com
General Queries.

View Proceedings of Previous Conferences

BABE  2015 Proceedings
BABE 2014 Proceedings
BABE 2013 Proceedings
BABE 2012 Proceedings
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.